Salix scoops up Santarus for $2.1bn in cash
Gastrointestinal-focused Salix Pharmaceuticals Ltd. is paying $2.1bn ($32.00 per share in cash; a 35% premium) to acquire all the outstanding stock of fellow public specialty pharmaco Santarus Inc. (acquires, develops, and sells physician specialty products).
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.